Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 18 clinical trials
Featured trial
FOURIER - Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk

FOURIER - Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk

  • 268 views
  • 25 Mar, 2021
  • 1 location
PCSK9 Inhibitor Treatment for Patients With SPG5

emerged as a new class of drugs that effectively lower cholesterol levels. Evolocumab, a member of this class, is a fully human monoclonal antibody that reduces LDL cholesterol levels by approximately 60

  • 9 views
  • 16 Feb, 2022
  • 1 location
Effect of Evolocumab on Saphenous Vein Graft Patency Following Coronary Artery Bypass Surgery (NEWTON-CABG)

The purpose of this study is to determine if evolocumab added to regular statin therapy improves vein graft patency after coronary artery bypass graft (CABG) surgery.

hmg-coa reductase inhibitor
simvastatin
cholesteryl ester transfer protein
atorvastatin
niacin
  • 28 views
  • 09 Feb, 2022
  • 9 locations
Evolocumab or Normal Strategies to Reach LDL Objectives in Acute Myocardial Infarction Upbound to PCI

an indication for PCI, using the PROBE study design (Prospective Randomised Open, Blinded Endpoint). The objective of this study is to demonstrate the superiority of evolocumab versus standard

  • 0 views
  • 10 Oct, 2021
Effect of Evolocumab on Coronary Plaque Characteristics (YELLOW III)

The aim of the study is to assess the effect of evolocumab on coronary plaque morphology using intravascular imaging and gene expression analysis of peripheral blood mononuclear cells (PBMC) in

hmg-coa reductase inhibitors
stenosis
bypass graft
percutaneous coronary intervention
angiography
  • 0 views
  • 14 May, 2022
  • 1 location
Lipid Management in Renal Transplant Recipients Using Evolocumab.

evaluate the safety and tolerability of Evolocumab (trade name: Repatha) which is a PCSK-9 inhibitor developed by Amgen, Inc in renal transplant recipients. The study would involve a total of 120 patients

  • 0 views
  • 13 May, 2021
  • 1 location
Effect of Evolocumab on Carotid Plaque Composition in Asymptomatic Carotid Artery Stenosis (EVOCAR-1)

This is a phase IV, randomised, placebo-controlled, double-blind, parallel group study to determine the effect of Evolocumab treatment on carotid plaque morphology and composition in

MRI
low-density lipoprotein
stenosis
ezetimibe
carotid artery stenosis
  • 0 views
  • 16 Sep, 2021
  • 1 location
A Randomized Pilot Study of Evolocumab Plus Nivolumab/Ipilimumab in Treatment-Naïve Patients With Metastatic NSCLC (TOP2101)

equal to 1%. Evolucumab is being combined with nivolumab and ipilimumab to see if it will improve the anti-tumor capabilities of the immunotherapy. Adding evolocumab to the combination of nivolumab and

  • 0 views
  • 03 Jun, 2022
  • 1 location
Effect of Evolocumab Added to Moderate-Intensity Statin Therapy on LDL-C Lowering and Cardiovascular Adverse Events in Patients With Acute Coronary Syndrome

The study is an open-label, multicenter, and randomized study(five hospitals).The purpose of this study is to assess the differences in the effects of the evolocumab added to moderate-intensity

  • 0 views
  • 27 Jan, 2021
  • 1 location
Impact of Evolocumab as an Additional Lipid-lowering Therapy to Changes in Lipid Core Burden Index of Non-culprit Vulnerable Plaque in Patients Who Underwent Percutaneous Coronary Intervention for the Acute Coronary Syndrome

This study aimed to investigate the impact of intensive cholesterol-lowering therapy (including evolocumab), drug treatment for high-risk plaques (Vulnerable plaques) with a high probability of

acute coronary syndrome
percutaneous coronary intervention
hmg-coa reductase inhibitors
  • 0 views
  • 27 Apr, 2022
  • 1 location